Real-world effectiveness (RWE) of dupilumab in reducing healthcare resource utilization among moderate-to-severe asthma patients
A. Pawar (Cambridge, MA, United States), M. Blaiss (Augusta, GA, United States), B. Modena (La Jolla, CA, United States), A. Khan (Chilly-Mazarin, France), L. De Prado Gómez (Reading, United Kingdom), Y. Zhang (Tarrytown, NY, United States), S. Siddiqui (Tarrytown, NY, United States), J. Jacob-Nara (Bridgewater, NJ, United States), L. De Prado Gomez (Reading, United Kingdom)
Source: International Congress 2022 – Asthma biologics in real life studies
Session: Asthma biologics in real life studies
Session type: Thematic Poster
Number: 2390
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Pawar (Cambridge, MA, United States), M. Blaiss (Augusta, GA, United States), B. Modena (La Jolla, CA, United States), A. Khan (Chilly-Mazarin, France), L. De Prado Gómez (Reading, United Kingdom), Y. Zhang (Tarrytown, NY, United States), S. Siddiqui (Tarrytown, NY, United States), J. Jacob-Nara (Bridgewater, NJ, United States), L. De Prado Gomez (Reading, United Kingdom). Real-world effectiveness (RWE) of dupilumab in reducing healthcare resource utilization among moderate-to-severe asthma patients. 2390
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|